Kelsey Desalvo
Endocrinology, Diabetes & Metabolism · Salt Lake City, UTNPI 1023437696
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.0%), education and consulting fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Cambridge Interventional LLC at 38.7% of the total. Reporting peaked in 2023 at $1,255 and has fallen 64.0% since, to $452 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in UT, where the typical reported total is $3,842.
Across 27 payments — averaging $99.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cambridge Interventional LLC$1K
- Abbott$293
- Medtronic$258
- Neurocrine Biosciences, Inc.$255
- Dexcom, Inc.$236
- Tandem Diabetes Care, Inc.$177
- plus $430 from 5 others
Across 2 payments — averaging $1762.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$4K
What the payments were for
- Consulting fees$2007%
- Food & beverage$1,53457%
- Education$95836%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cambridge Interventional LLC | 3 | $1,043 |
| Abbott | 2 | $293 |
| Medtronic(2 entities) | 3 | $258 |
| Neurocrine Biosciences, Inc. | 3 | $255 |
| Dexcom, Inc. | 4 | $236 |
| Tandem Diabetes Care, Inc. | 4 | $177 |
| Insulet Corporation | 1 | $130 |
| Amgen | 1 | $122 |
| BETA Bionics, Inc. | 3 | $120 |
| Mannkind Corporation | 2 | $44 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRF$958
- FreeStyle Libre$158
- MINIMED 780G$154
- FreeStyle Libre Pro$135
- Omnipod$130
- DEXCOM G7 GSS (161)$122
- Prolia$122
How this compares
$2,692 in reported general payments places this provider in the 40th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 12 | $53,074 |
| TymlosAbaloparatide | 12 | $36,549 |
| TrulicityDulaglutide | 17 | $20,674 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $5,916 |
| SynthroidLevothyroxine Sodium | 48 | $5,835 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $5,321 |
| Hydrocortisone | 40 | $3,722 |
| Levothyroxine Sodium | 281 | $3,626 |
| Testosterone | 29 | $3,122 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,078 |
| Methimazole | 133 | $1,397 |
| Liothyronine Sodium | 27 | $1,259 |
| Cinacalcet Hcl | 15 | $1,016 |
| Alendronate Sodium | 87 | $780 |
| Calcitriol | 12 | $611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Trulicity | $15 | $73,74729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
Other endocrinology, diabetes & metabolism in Salt Lake City
- Eliot BrintonSalt Lake City$733K
- Alireza Falahati-NiniSalt Lake City$241K
- Shahzad AhmadSalt Lake City$25K
- Vishnu SundareshSalt Lake City$18K
- Bruce BradySalt Lake City$5K
- Barry BenowitzSalt Lake City$4K
- Marie CouldwellSalt Lake City$3K
- Sneha WagleSalt Lake City$257
- Javier Munoz BarreraSalt Lake City$160
- Ross HeinrichSalt Lake City$122
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.